Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone

References

• Alfa, H.H. and Arroo, R.R.J., 2019. Over 3 decades of research on dietary flavonoid antioxidants and cancer prevention: what have we achieved? Phytochemistry reviews, 18 (4), 989–1004.
   Web of Science ®Google Scholar
• Bianco, M.-A. and Savolainen, H., 1994. Woodworkers’ exposure to tannins. Journal of applied toxicology : JAT, 14 (4), 293–295.
   PubMed Web of Science ®Google Scholar
• Bonifácio, M.J., et al., 2002. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Molecular pharmacology, 62 (4), 795–805.
   PubMed Web of Science ®Google Scholar
• Borges, N., et al., 1997. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. The journal of pharmacology and experimental therapeutics, 282 (2), 812–817.
   PubMed Web of Science ®Google Scholar
• Cavalieri, E., et al., 2006. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et biophysica acta, 1766 (1), 63–78.
   PubMed Web of Science ®Google Scholar
• Cavalieri, E., Rogan, E., and Chakravarti, D., 2004. The role of endogenous catechol quinones in the initiation of cancer and neurodegenerative diseases. Methods in enzymology, 293–319.
   PubMed Web of Science ®Google Scholar
• Davies, B. and Morris, T., 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical research, 10 (7), 1093–1095.
   PubMed Web of Science ®Google Scholar
• De Santi, C., et al., 1998. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. European journal of clinical pharmacology, 54 (3), 215–219.
   PubMed Web of Science ®Google Scholar
• Ellingson, T., et al., 1999. Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. Journal of chromatography B: biomedical sciences and applications, 729 (1-2), 347–353.
   PubMed Web of Science ®Google Scholar
• Forsberg, M., et al., 2003. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. The journal of pharmacology and experimental therapeutics, 304 (2), 498–506.
   PubMed Web of Science ®Google Scholar
• Gonzalez, F. J., Coughtrie, M., and Tukey, R. H., 2018. Drug metabolism. In: L.L. Brunton, R. Hilal-Dandan, B.C. Knollman, eds. Goodman & Gilmans’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 85–100.
   Google Scholar
• Heikkinen, A.T., et al., 2015. Quantitative ADME proteomics – CYP and UGT enzymes in the Beagle dog liver and intestine. Pharmaceutical research, 32 (1), 74–90.
   PubMed Web of Science ®Google Scholar
• Johnson, K., et al., 2003. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug metabolism and disposition: the biological fate of chemicals, 31 (1), 76–87.
   PubMed Web of Science ®Google Scholar
• Kiss, L.E. and Soares-da-Silva, P., 2014. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. Journal of medicinal chemistry, 57 (21), 8692–8717.
   PubMed Web of Science ®Google Scholar
• Kurkela, M., et al., 2004. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase. Analytical biochemistry, 331 (1), 198–200.
   PubMed Web of Science ®Google Scholar
• Lantz, R.J., et al., 2003. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug metabolism and disposition: the biological fate of chemicals, 31 (9), 1142–1150.
   PubMed Web of Science ®Google Scholar
• Lautala, P., Ulmanen, I., and Taskinen, J., 1999. Radiochemical high-performance liquid chromatographic assay for the determination of catechol O-methyltransferase activity towards various substrates. Journal of chromatography B: biomedical sciences and applications, 736 (1-2), 143–151.
   PubMed Web of Science ®Google Scholar
• Lekse, J., et al., 2001. Plant catechols prevent lipid peroxidation in human plasma and erythrocytes. Molecular and cellular biochemistry, 226 (1-2), 89–95.
   PubMed Web of Science ®Google Scholar
• Luttringer, O., et al., 2003. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. Journal of pharmaceutical sciences, 92 (10), 1990–2007.
   PubMed Web of Science ®Google Scholar
• Ma, Z., Liu, H., and Wu, B., 2014. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders. British journal of clinical pharmacology, 77 (3), 410–420.
   PubMed Web of Science ®Google Scholar
• Männistö, P.T. and Kaakkola, S., 1999. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacological reviews, 51 (4), 593–628.
   PubMed Web of Science ®Google Scholar
• Männistö, P. T., et al., 1992., Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. In: E. Jucker, ed. Progress in drug research/Fortschritte der arzneimittelforschung/Progrès des recherches pharmaceutiques. Basel: Birkhäuser, 291–350.
   Google Scholar
• Myöhänen, T.T. and Männistö, P.T., 2010. Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? International review of neurobiology, 95, 29–47.
   PubMed Web of Science ®Google Scholar
• Myöhänen, T.T., Schendzielorz, N., and Männistö, P.T., 2010. Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. Journal of neurochemistry, 113 (6), 1632–1643.
   PubMed Web of Science ®Google Scholar
• Palma, P.N., et al., 2003. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug metabolism and disposition: the biological fate of chemicals, 31 (3), 250–258.
   PubMed Web of Science ®Google Scholar
• Parkinson, A., et al., 2019. Biotransformation of xenobiotics. In: C.D. Klaassen, ed. Casarett & Doull’s toxicology: the basic science of poisons. 9th ed. New York: Mc Graw Hill Education, 193–399.
   Google Scholar
• Reenilä, I., Tuomainen, P., and Männistö, P.T., 1995. Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. Journal of chromatography B: biomedical sciences and applications, 663 (1), 137–142.
   Web of Science ®Google Scholar
• Reid, A.-M., et al., 2019. In vitro human metabolism and inhibition potency of verbascoside for CYP enzymes. Molecules, 24 (11), 2191.
   PubMed Web of Science ®Google Scholar
• Rhodes, L.E., et al., 2013. Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid. The British journal of nutrition, 110 (5), 891–900.
   PubMed Web of Science ®Google Scholar
• Riishede, L. and Nielsen-Kudsk, F., 1990. Myocardial effects of adrenaline, isoprenaline and dobutamine at hypothermic conditions. Pharmacology & toxicology, 66 (5), 354–360.
   PubMedGoogle Scholar
• Sak, K., 2017. Intake of individual flavonoids and risk of carcinogenesis: overview of epidemiological evidence. Nutrition and cancer, 69 (8), 1119–1150.
   PubMed Web of Science ®Google Scholar
• Sanders-Bush, E. and Hazelwood, L., 2015. 5-Hydroxytryptamine (serotonin) and dopamine. In: L.L. Brunton, B.A. Chabner, and B.C. Knollmann, eds. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York, NY: McGraw-Hill Education.
   Google Scholar
• Schultz, E. and Nissinen, E., 1989. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochemical pharmacology, 38 (22), 3953–3956.
   PubMed Web of Science ®Google Scholar
• Slominski, A., et al., 2004. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological reviews, 84 (4), 1155–1228.
   PubMed Web of Science ®Google Scholar
• Su, A.I., et al., 2002. Large-scale analysis of the human and mouse transcriptomes. Proceedings of the National Academy of Sciences of the United States of America, 99 (7), 4465–4470.
   PubMed Web of Science ®Google Scholar
• Tenhunen, J., et al., 1993. Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme. DNA and cell biology, 12 (3), 253–263.
   PubMed Web of Science ®Google Scholar
• Tenhunen, J., et al., 1994. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. European journal of biochemistry, 223 (3), 1049–1059.
   PubMedGoogle Scholar
• Testa, B. and Krämer, S.D., 2008. The biochemistry of drug metabolism-an introduction: part 4. reactions of conjugation and their enzymes. Chemistry & biodiversity, 5 (11), 2171–2336.
   PubMed Web of Science ®Google Scholar
• Veser, J., 1987. Kinetics and inhibition studies of catechol O-methyltransferase from the yeast Candida tropicalis. Journal of bacteriology, 169 (8), 3696–3700.
   PubMed Web of Science ®Google Scholar
• Wikberg, T., et al., 1993. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug metabolism and disposition: the biological fate of chemicals, 21 (1), 81–92.
   PubMed Web of Science ®Google Scholar
• Yager, J.D., 2012. Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug discovery today. Disease mechanisms, 9 (1-2), e41–e46.
   PubMedGoogle Scholar
• Yang, J., Cohen Stuart, M.A., and Kamperman, M., 2014. Jack of all trades: versatile catechol crosslinking mechanisms. Chemical society reviews, 43 (24), 8271–8298.
   PubMed Web of Science ®Google Scholar
• Zhu, B.T., 2004. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson’s disease. International journal of molecular medicine, 13 (3), 343–353.
   PubMed Web of Science ®Google Scholar
• Zucca, F.A., et al., 2014. Neuromelanin of the human substantia nigra: an update. Neurotoxicity research, 25 (1), 13–23.
   PubMed Web of Science ®Google Scholar